Development

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

Vectura’s expertise in the field includes formulation and device development for dry powder inhalers and pressurized metered dose inhalers, among other products and services.

Phillips Medisize to Acquire Vectura, Expanding Inhalation Drug Delivery Capabilities

Videos

For a preview of what's to come at the AAPS PharmSci 360 show in October, Pharmaceutical Technology® spoke with Vivek Gupta, PhD, associate dean for Graduate Education and Research, associate professor, Pharmaceutical Sciences, St. John’s University, Queens, New York, about the formulation of inhalation dosage forms.

AAPS PharmSci 360 2024: Developing Inhalation Drugs

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Pharmaceutical Technology Europe® spoke with Gustavo Ferrer from Dr. Ferrer BioPharma, a US company focused on innovative intranasal medications, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Improving Intranasal Treatments with Dr. Ferrer BioPharma at CPHI Barcelona

A novel approach for safety assessments in inhalation drugs may avoid animal testing for drug products.

Breathing Easier

Shabbir Mostafa, head of Business Development — Advanced Delivery Systems, Recipharm, sat down with Grant Playter, associate editor, during DCAT week to discuss the current state of inhalations forms and drug delivery. 

Investigating Inhalation Forms and Drug Delivery with Shabbir Mostafa (DCAT Week)

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs. 

Inhalation Vaccine Development

It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.

Delivering a Difference in Formulation

Inhalation formulations are complex, and empirical data are essential for realizing optimal solutions.

Inhalation Formulation Development: Predicting API Behavior

Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.

Formulation and Drug Delivery, Inhalation Drugs